CD99Targeted Irinotecan Containing Nanoparticles Show Twenty-Fold Greater Anti-Tumor Effect Than Free Irinotecan For Treatment of Ewing Sarcoma.

ABSTRACT:

Purpose

To assess the antitumor efficacy, pharmacokinetics, and safety of NV103, a CD99-targeted liposomal irinotecan nanoparticle, in a preclinical Ewing sarcoma model.

Experimental design

NV103 is a CD99-antibody targeted irinotecan containing nanoparticle, engineered to selectively deliver irinotecan to CD99 expressing tumor cells. In vitro studies measured binding, internalization, and cytotoxic IC₅₀ values in several Ewing sarcoma cell lines. In vivo, mice bearing xenografts derived from treatment-naïve and chemoresistant Ewing lines were treated. NV103 was compared with free irinotecan, untargeted nanoparticles, and Onivyde^™ at multiple dosages. Plasma pharmacokinetics of irinotecan and SN-38, biodistribution of the nanoparticles, an

SUBMITTER: Kang HG 

PROVIDER: S-EPMC12803216 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature